# Continuation Protocol to Protocol BBCO-001

> **NCT02328482** · PHASE3 · COMPLETED · sponsor: **Bioblast Pharma Ltd.** · enrollment: 9 (actual)

## Conditions studied

- Muscular Dystrophy, Oculopharyngeal (OPMD)

## Interventions

- **DRUG:** Tehalose 30gr

## Key facts

- **NCT ID:** NCT02328482
- **Lead sponsor:** Bioblast Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2017-10
- **Final completion:** 2017-12
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02328482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02328482, "Continuation Protocol to Protocol BBCO-001". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02328482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*